Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
SUZHOU, China and MÖLNDAL, Sweden, May 6, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (“Ribo”, HKEX: 6938) today announced the achievement of a further milestone. This
